Orris

Can we give aspirin to hemophilia patient

Reading File
Finding Sources
Finding Sources
Searching PubMed

"hemophilia A"[MeSH Terms] AND "aspirin"[MeSH Terms]

Searching the Web

hemophilia antiplatelet aspirin use cardiovascular disease guidance WFH safety

Searching PubMed

"hemophilia"[MeSH Terms] AND "antiplatelet"

Reading Web Page

https://pmc.ncbi.nlm.nih.gov/articles/PMC10256340

Short answer: Usually no. Aspirin should be avoided in hemophilia. It can be given only in a narrow set of cases, when there is a clear compelling indication (for example, established coronary disease, stroke/TIA, or a stent). Even then, the factor levels must be covered and a hematologist and cardiologist should be involved.
Why it is avoided
  • Aspirin irreversibly inhibits platelet COX-1 for the platelet's lifespan (about 7 to 10 days). This adds a platelet defect on top of the clotting factor deficiency. It also causes gastric mucosal injury, so GI and joint bleeds are more likely.
  • Katzung's pharmacology text says "The antiplatelet action of aspirin contraindicates its use by patients with hemophilia" - Katzung's Basic and Clinical Pharmacology, 16th Edition (Aspirin section).
  • Goodman & Gilman lists hemophilia among the conditions in which aspirin should be avoided - Goodman & Gilman's The Pharmacological Basis of Therapeutics (Adverse Effects and Toxicity).
  • Hemophilia centers advise avoiding aspirin and other platelet-inhibiting drugs - Goldman-Cecil Medicine (General Care).
Practical rules for routine use
  • Pain or fever: Use paracetamol (acetaminophen). Avoid aspirin. Avoid non-selective NSAIDs too. A COX-2 inhibitor may be considered with specialist input.
  • Children: Avoid aspirin. It also carries the Reye syndrome risk.
  • Pre-procedure: Stop platelet inhibitors (aspirin, clopidogrel, prasugrel, NSAIDs) before surgery - Miller's Review of Orthopaedics, 9th ed.
  • Lab effect: Aspirin does not change the aPTT or PT. The hemophilia defect itself prolongs the aPTT - Lippincott Biochemistry, 8th ed.
When aspirin may be justified
Hemophilia does not protect against atherosclerosis, and patients are now living long enough to develop heart disease and stroke. The 2023 EHA-ISTH-EAHAD-ESO guidance and the WFH guidelines say the following:
  • Indication: Use aspirin only for a strong indication such as secondary prevention after MI, stroke/TIA, or PCI. Primary prevention in the general population gives a small benefit and a higher bleeding risk, so it is not a reason to use aspirin in a person with hemophilia.
  • Factor cover: Single antiplatelet therapy (aspirin or clopidogrel) requires FVIII/FIX trough levels of at least 1 to 5 IU/dL.
  • Dual antiplatelet therapy: A trough of at least 20 IU/dL is needed.
  • Severe hemophilia: Use regular prophylaxis with the antiplatelet. Do not give any antithrombotic to a patient with severe hemophilia who is not on prophylaxis.
  • Inhibitors: Do not give any antithrombotic to patients with inhibitors unless they are on emicizumab.
  • Atrial fibrillation: The guidance recommends against using aspirin in place of anticoagulation.
  • Post-PCI: One expert review suggests keeping dual antiplatelet therapy as short as possible, about 4 weeks after the stent, then long-term low-dose aspirin 80 to 100 mg - Haematologica review.
  • Who decides: The WFH says the decision should always be made with a cardiologist and after assessing the individual's bleeding and thrombotic risk.
Evidence check: My PubMed search for recent (last 2 years) systematic reviews and meta-analyses on hemophilia and antiplatelets returned nothing relevant. The textbooks and the 2023 guidance above are consistent with each other. The guidance is largely consensus-based because randomized data do not exist.
If you have a specific patient in mind, tell me the hemophilia type and severity, inhibitor status, and the indication. I can then be more specific.
This is a shared conversation. Sign in to Orris to start your own chat.